论文部分内容阅读
目的研究分析危重患者贫血治疗中促红细胞生成素的应用效果。方法将2014年3月至2016年2月额敏县人民医院接收的64例危重患者用随机数字表法分为对照组和试验组,各32例。所有患者均存在贫血现象需进行贫血治疗,两组都采用常规治疗,对照组患者在此基础上给予铁剂与维生素B12治疗,而试验组患者则用重组促红细胞生成素治疗,比较两组患者治疗后Hb(外周静脉血血红蛋白)、RET(网织红细胞)以及输血率。结果试验组和对照组患者治疗后Hb、RET计数比较,差异具有统计学意义(P<0.05);在输血率方面,试验组明显低于对照组,差异具有统计学意义(P<0.05)。结论在危重患者贫血治疗中应用促红细胞生成素,可有效提高患者网织红细胞计数,增加其Hb含量,降低输血率,效果明显,临床应用推广价值较高。
Objective To study the application of erythropoietin in the treatment of critically ill patients with anemia. Methods From March 2014 to February 2016, 64 critically ill patients received by Eminon County People’s Hospital were divided into control group and experimental group by random number table method, 32 cases in each group. All patients had anemia, which required anemia treatment. Both groups were treated with conventional therapy. Patients in the control group were given iron supplementation and vitamin B12 on the basis of this treatment while patients in the experimental group were treated with recombinant erythropoietin. Patients in both groups Hb (peripheral venous hemoglobin), RET (reticulocyte) and blood transfusion after treatment. Results Compared with control group, Hb and RET counts were statistically significant (P <0.05). The blood transfusion rate was significantly lower in the experimental group than in the control group (P <0.05). Conclusion The application of erythropoietin in the treatment of anemia in critically ill patients can effectively improve the reticulocyte count, increase the content of Hb and reduce the blood transfusion rate. The effect is obvious, and the value of clinical application is high.